Peptide Regulatory Submission Timelines: Planning for FDA and EMA Approvals

Timing is everything when it comes to regulatory submissions. Missing a deadline or submitting too late can cost your peptide drug months or even years of delay.

This guide lays out the key timelines for major regulatory submissions. It will help you plan your development program from start to finish.

Overview of Key Regulatory Submissions

Peptide drug development involves many regulatory submissions. Each one has its own timeline, requirements, and review process.

Here is a quick look at the major submissions you will encounter.

Submission Type	Agency	Purpose	Typical Review Time
Pre-IND Meeting Request	FDA	Early guidance on development plan	60-90 days to schedule
IND Application	FDA	Permission to start clinical trials	30 days
End-of-Phase 2 Meeting	FDA	Guidance on Phase 3 design	60-90 days to schedule
NDA/BLA	FDA	Drug approval request	10-12 months (standard)
MAA	EMA	Marketing authorisation in EU	210 days (active review)
Orphan Drug Designation	FDA	Rare disease status	90 days
Breakthrough Therapy	FDA	Expedited development	60 days

Planning Your Submission Timeline

Good planning starts early. You should have a regulatory strategy in place before you begin clinical trials.

Work backwards from your target approval date. This helps you set deadlines for each submission and milestone.

Key Planning Factors

• The complexity of your peptide drug
• Your clinical trial design and enrollment timeline
• Manufacturing readiness
• Staffing and resource availability
• Budget constraints

"I always tell my clients to add at least 6 months of buffer to every timeline. Regulatory submissions almost always take longer than you think, especially for complex peptide products," advises Dr. Karen Li, a regulatory affairs vice president who has led five successful NDA submissions for peptide drugs.

Pre-IND Phase: Before Clinical Trials

Before you can test your peptide drug in humans, you need to do a lot of preparation. This phase can take 2 to 5 years.

Preclinical Development Timeline

Activity	Typical Duration
Lead peptide identification	6-18 months
Preclinical pharmacology studies	6-12 months
Toxicology studies (GLP)	6-12 months
Manufacturing process development	12-24 months
Analytical method development	6-12 months
IND preparation	3-6 months

Pre-IND Meeting

A Pre-IND meeting with the FDA is optional but highly recommended. It gives you a chance to discuss your development plan before committing significant resources.

Submit your meeting request at least 90 days before your desired meeting date. Include a detailed briefing document with your questions and supporting data.

The FDA will respond with written feedback if they agree to a meeting. This feedback is extremely valuable for shaping your development strategy.

IND Application Timeline

The IND (Investigational New Drug) application is your ticket to start clinical trials. The FDA review takes exactly 30 calendar days.

IND Preparation Timeline

Start preparing your IND at least 6 months before your planned submission date. This gives you time to compile all the required sections.

Your IND must include three main sections: chemistry, manufacturing, and controls (CMC), preclinical data, and your clinical protocol.

What Happens During the 30-Day Review

After you submit your IND, the FDA has 30 days to review it. If they do not place a clinical hold, you can begin your clinical trial on Day 31.

If the FDA has concerns, they may place a clinical hold. This means you cannot start your trial until the concerns are resolved. Clinical holds can add weeks or months to your timeline.

According to the FDA's CDER annual report, the agency receives thousands of IND applications each year. The majority are allowed to proceed without a clinical hold, but having a well-prepared submission increases your chances significantly.

Clinical Trial Phase Timelines

Each clinical trial phase has its own timeline. These are averages and can vary significantly.

Phase	Average Duration	Key Milestone at End
Phase 1	6-12 months	Safety data, dose selection
Phase 2	12-24 months	Proof of concept, dose optimization
Phase 3	24-48 months	Pivotal efficacy and safety data

Between Phase Submissions

Between each clinical phase, you need to update your IND. These updates include new protocols, safety reports, and updated CMC information.

Annual reports are also required. These summarize the progress of your clinical program over the past year.

For a deeper look at moving between phases, see our guide on peptide clinical trial phase transitions.

NDA/BLA Submission Timeline

The NDA (New Drug Application) or BLA (Biologics License Application) is the big one. This is your formal request for FDA approval to market your peptide drug.

Preparing for Submission

Start preparing your NDA or BLA at least 12 to 18 months before your planned submission date. This sounds like a long time, but there is a lot to do.

You need to compile clinical data, CMC data, nonclinical data, and labeling. You also need to prepare the electronic Common Technical Document (eCTD) submission.

Pre-NDA/Pre-BLA Meeting

Request a Pre-NDA or Pre-BLA meeting with the FDA about 6 months before submission. This meeting helps you understand what the FDA expects in your application.

Discuss the format of your submission, key issues the FDA wants addressed, and any data gaps that need to be filled.

FDA Review Timeline

Review Type	Timeline	Criteria
Standard Review	10-12 months	Default for most drugs
Priority Review	6-8 months	Significant improvement over existing treatment
Accelerated Approval	Variable	Surrogate endpoint for serious conditions
Breakthrough Therapy	Variable	Substantial improvement, intensive FDA guidance

PDUFA Date

The FDA commits to completing its review by the PDUFA (Prescription Drug User Fee Act) date. This date is set when the FDA accepts your application for filing.

The PDUFA date is not a guarantee of approval. It is the date by which the FDA will make a decision (approve, request more information, or issue a complete response letter).

EMA Submission Timeline

If you plan to market your peptide drug in Europe, you will submit a Marketing Authorisation Application (MAA) to the European Medicines Agency.

Centralised Procedure Timeline

The centralised procedure is the most common route for peptide drugs in Europe. It gives you a single approval valid in all EU member states.

Stage	Timeline
Pre-submission meeting	6-12 months before MAA
MAA submission	Day 0
Validation	10 days
Assessment	Day 1 to Day 120
Clock stop for responses	Variable (3-6 months)
Second assessment	Day 121 to Day 180
Opinion	Day 210
EC Decision	67 days after opinion

Parallel Submissions

Many companies submit to the FDA and EMA at the same time, or close together. This requires careful planning to manage the different requirements and timelines.

Consider using the same eCTD format for both submissions. This saves time and ensures consistency.

Expedited Programs

The FDA offers several programs to speed up the development and review of promising drugs. Peptide drugs may qualify for one or more of these programs.

• Fast Track: More frequent FDA meetings and rolling review
• Breakthrough Therapy: Intensive FDA guidance and organizational commitment
• Accelerated Approval: Approval based on surrogate endpoints
• Priority Review: Shorter review timeline (6 months instead of 10)

Apply for these designations as early as possible. They can significantly shorten your overall timeline.

Common Timeline Delays

Many peptide drug programs experience delays. Here are the most common causes.

• Clinical trial enrollment takes longer than expected
• Manufacturing issues during scale-up
• FDA information requests during review
• Unexpected safety findings
• Data quality issues requiring re-analysis
• Advisory committee scheduling delays

How to Minimize Delays

Plan for the unexpected. Build buffer time into your timeline.

Communicate with the FDA regularly. Use scheduled meetings to address potential issues early.

Invest in manufacturing readiness. Make sure your CMC package is complete before you submit your NDA or BLA.

For help building a regulatory team that can keep your submissions on track, explore our regulatory affairs career guide.

Frequently Asked Questions

How long does it take to get a peptide drug approved from start to finish?

The entire process from preclinical development to FDA approval typically takes 10 to 15 years. This includes preclinical research (2-5 years), clinical trials (5-8 years), and FDA review (1-2 years). Some peptide drugs with expedited designations have been approved in shorter timeframes.

Can I submit an NDA and MAA at the same time?

Yes, and many companies do. Submitting to both the FDA and EMA simultaneously or within a few months of each other is common practice. However, you need to manage the different requirements and respond to questions from both agencies, which requires significant resources.

What is a rolling submission?

A rolling submission allows you to submit completed sections of your NDA or BLA as they are ready, rather than waiting until the entire application is finished. This is available to drugs with Fast Track designation and can save several months on the overall timeline.

How do I handle FDA information requests during review?

The FDA may send information requests (IRs) during their review of your NDA or BLA. Respond quickly and completely. The review clock is usually paused while you prepare your response, so delays in responding directly delay your PDUFA date.

What happens if the FDA issues a Complete Response Letter?

A Complete Response Letter (CRL) means the FDA has not approved your application and is asking for additional information or changes. This is not the end of the road. You can address the issues and resubmit. However, a CRL typically adds 6 to 18 months to your timeline.

How far in advance should I start planning my regulatory submission?

Start planning your regulatory strategy at the beginning of your development program, ideally 2 to 3 years before your first submission. For the NDA or BLA specifically, begin detailed preparation at least 12 to 18 months before the target submission date.

Final Thoughts

Regulatory submission timelines are long and complex, but they are manageable with proper planning. Start early, communicate with regulators, and build in buffer time.

Every day saved in the regulatory process is a day sooner that patients can access your peptide therapy. That is motivation enough to get your timelines right.

Keep this guide handy as a reference throughout your development program. Review it regularly and adjust your plans as needed based on your specific situation.